The marketing authorization of a medicinal product represents a major milestone in its development, but it does not mark the end of its safety evaluation. Once approved, a medicine enters routine clinical practice, where it is used in broader and more heterogeneous populations than those included in clinical trials. This makes the safety profile more complex, but also more representative of how the product is actually used in real-world settings.
At this stage, risks that were not identified before authorization may emerge, including rare adverse reactions, long-term effects, or issues related to the use of the medicine in patient populations that were underrepresented in pre-approval studies. For this reason, the evaluation of a medicine’s benefit-risk profile does not end at authorization but continues throughout its lifecycle through post-marketing pharmacovigilance activities.
Where safety data come from
Post-marketing pharmacovigilance relies on the collection and integration of data from multiple sources. Each source has its own characteristics and level of robustness, yet all contribute to the ongoing assessment of a medicinal product’s safety profile.
Spontaneous reporting of suspected adverse reactions remains the cornerstone of pharmacovigilance. Physicians, pharmacists, and patients can report events observed in routine clinical practice, helping to identify potential safety signals at an early stage. Although these reports are often heterogeneous and not always complete, they are highly sensitive in detecting rare or unexpected events that are unlikely to emerge during pre-authorization clinical trials.
Alongside spontaneous reporting, structured data sources play an increasingly important role. Observational studies, for example, allow the evaluation of real-world use of a medicine in large populations, making it possible to estimate the frequency of adverse events and investigate potential risk factors. Patient registries, often focused on specific diseases or treatments, provide longitudinal data that can be used to assess long-term effects and safety in particular subgroups of patients.
Scientific literature also contributes significantly through case reports, case series, and post-marketing studies, which may confirm or further investigate signals identified through other sources. Additional information may come from patient support programs and organized data collection systems established by pharmaceutical companies or regulatory authorities, allowing closer monitoring of specific conditions of use.
Through the integration of these various data sources, a medicine’s safety profile is continuously updated based on evidence generated in real-world clinical practice.
From signal detection to risk management
The integration of safety data from multiple sources enables not only the identification of new safety signals but also the evaluation of their clinical relevance and regulatory impact. A signal does not necessarily indicate a proven causal relationship; rather, it represents information that requires further investigation.
The association between a medicinal product and an event is assessed through a structured process that considers several factors, including the frequency of reports, consistency across cases, biological plausibility, and the temporal relationship between exposure to the medicine and the occurrence of the event.
The combined analysis of individual cases and aggregated datasets helps identify recurring patterns and assess their significance based on the totality of available evidence.
When signal evaluation confirms clinical or regulatory relevance, various actions may be taken. These can include updates to product information, the introduction of new warnings or precautions, the publication of safety communications such as Direct Healthcare Professional Communications (DHPCs), or the implementation of additional risk minimization measures.
In the most critical situations, where risks are considered to outweigh the benefits, regulatory authorities may impose restrictions on the use of the medicine or, in exceptional circumstances, withdraw it from the market.
The impact on patient safety and regulatory decisions
Post-marketing pharmacovigilance plays a fundamental role in ensuring that medicinal products continue to be used safely throughout their commercial lifecycle.
The ability to identify emerging risks in a timely manner allows regulatory authorities and pharmaceutical companies to take appropriate actions before safety issues become widespread. At the same time, the continuous assessment of real-world data contributes to a better understanding of how medicines perform outside controlled clinical trial environments.
This information supports both regulatory decision-making and clinical practice by providing healthcare professionals with updated safety information and helping patients receive treatments with a favorable benefit-risk balance.
As additional evidence becomes available over time, post-marketing pharmacovigilance contributes to refining the knowledge of a medicine’s safety profile and ensuring that risk management measures remain effective and proportionate.
Conclusions
Post-marketing pharmacovigilance is an essential component of medicinal product safety once a medicine enters routine clinical practice.
Through the continuous collection and analysis of safety data, it enables the early identification of new risks and supports timely interventions aimed at protecting patients and promoting the appropriate use of medicines.
Over the long term, the information generated through post-marketing surveillance allows the benefit-risk profile of a medicinal product to be continuously updated, supporting informed decisions by both regulators and healthcare professionals.
In this perspective, pharmacovigilance is not a one-time activity but a continuous process that accompanies the entire lifecycle of a medicinal product, helping to ensure its safe use over time.
References
- World Health Organization. The importance of pharmacovigilance: Safety monitoring of medicinal products
- Directive 2001/83/EC
- Regulation (EC) No. 726/2004
- EMA – Good Pharmacovigilance Practices (GVP)
- FDA – Postmarketing surveillance guidance